Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma.

Pharmacogenetics and genomics - 1 Oct 2014

Goričar Katja, Kovač Viljem, Jazbec Janez, Zakotnik Branko, Lamovec Janez, Dolžan Vita

Abstract excerpt

OBJECTIVES: Osteosarcoma is the most common primary bone malignancy that occurs mostly in adolescents. Treatment protocols usually include multiagent preoperative and postoperative chemotherapy based on methotrexate, cisplatin, doxorubicin and ifosfamide. Despite a favourable prognosis, there are considerable interindividual differences in treatment outcome. Genetic variability of enzymes involved in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Bone Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Folic Acid

Share to Liver-Specific Organic Anion Transporter 1

Share to Methotrexate

Share to Organic Anion Transporters

Share to Osteosarcoma

Share to Survival Analysis

Source

Identifiers

PMID: 25098908
DOI: 10.1097/FPC.0000000000000083

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma.PMID 25098908Read ↗

Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study.Semantic proximity Read ↗

ABCC2(rs717620), and ABCC3 (rs4793665) affect high dose Methotrexate toxicity, and outcome in children with osteosarcomaSemantic proximity Read ↗

A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial.Semantic proximity Read ↗

Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcomaSemantic proximity Read ↗

Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate.Semantic proximity Read ↗

The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients.Semantic proximity Read ↗

Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: a systematic review of 2010-2020Semantic proximity Read ↗

Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study.Semantic proximity Read ↗

Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 ProtocolSemantic proximity Read ↗

Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy.Semantic proximity Read ↗

Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.Semantic proximity Read ↗

Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.